Security key
00773J202
Spyre Therapeutics, Inc. - Common Stock, $0.0001 par value (SYRE)
CUSIP: 00773J202
Q1 2026 13F Holders as of 31 Mar 2026
- Security type / class
- Equity / Common Stock, $0.0001 par value
- Total 13F shares
- 82,649,625
- Total 13F value
- $4,162,740,265
- Share change
- +1,471,731
- Put/Call ratio
- 8.8%
- SEC-reported price per share
- $50.44
- Number of holders
- 196
- Value change
- +$97,012,962
- Number of buys
- 115
- Number of sells
- 59
- Shares outstanding
- 88,583,250
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2026
Institutions
196
Top holders
10
SYRE full security history
Ownership snapshot
Full 13F holder table
Spyre Therapeutics, Inc. SEC filings
Spyre Therapeutics, Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of SYRE - Spyre Therapeutics, Inc. - Common Stock, $0.0001 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BlackRock, Inc.
Disclosed value leader
FMR LLC
Comparable rows
15/15
Latest evidence
31 Dec 2025
13F
13D/G
Lead comparable stake: 6.6%
13D/G row: BlackRock, Inc.
Showing 1-6 of 15 holder rows.
Quick read
BlackRock, Inc. leads the comparable SEC ownership view at 6.6%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BlackRock, Inc.'s linked filing trail.
Comparable ownership
Top 5
BlackRock, Inc.
6.6%
Venrock Healthcare Capital Partne...
4.6%
TANG CAPITAL MANAGEMENT LLC
2.4%
FMR LLC
13%
RTW INVESTMENTS, LP
4.7%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BlackRock, Inc. |
13F
13D/G
Company
|
6.6%
from 13D/G
|
$180,904,030
5,522,101 shares
|
— | 31 Dec 2025 |
| Venrock Healthcare Capital Partners III, L.P. |
13D/G
|
4.6%
|
$40,335,429
2,685,448 shares
|
$0 | 31 Dec 2024 |
| TANG CAPITAL MANAGEMENT LLC |
13D/G
13F
Company
|
2.4%
|
$62,064,160
1,892,200 shares
|
-$42,895,840 | 31 Dec 2025 |
| FMR LLC |
13F
Company
|
13%
|
$381,287,711
11,638,819 shares
|
— | 31 Dec 2025 |
| RTW INVESTMENTS, LP |
13F
Company
|
4.7%
|
$136,674,589
4,171,996 shares
|
— | 31 Dec 2025 |
| VANGUARD GROUP INC |
13F
Company
|
4.6%
|
$132,189,024
4,035,074 shares
|
— | 31 Dec 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
196
Shares
82,649,625
Rows available
196
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2026 vs Q1 2026 Across Filers
Q1 2026 holders
196
Q1 2026 holders
196
Holder diff
0
| Investor | Q1 2026 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q1 2026 value | Value change | Value Chg % |
|---|